February 21, 2024Open Access

Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials

FWFrank J. WoltersPreventive Cardiology JLJeremy A. LabrecqueErasmus MC

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Adverse effects of monoclonal antibodies against amyloid beta are common, and may affect validity of randomized controlled trials (RCTs) through unblinding of participants.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Wolters et al. (Wed,) studied this question.

synapsesocial.com/papers/68e7832ab6db6435876f5fdd https://doi.org/https://doi.org/10.1002/alz.13690

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Turning a blind eye:Testing the success of blinding and the CONSORT statement2004 · 41 citations
2Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures.2006 · 20 citations
3Identifying baseline characteristics of placebo responders <i>versus</i> nonresponders in randomized double‐blind trials of refractory partial‐onset seizures2006 · 18 citations
4Commentary: Measuring the success of blinding in RCTs: don't, must, can't or needn't?2007 · 162 citations
5Effect of fish oil on cognitive performance in older subjects2008 · 381 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo